Interstitial lung disease (ILD) encompasses a diverse group of pulmonary disorders characterized by inflammation and fibrosis of the lung interstitium, leading to progressive respiratory failure. According to a 2024 study by Francesco Puppo et al., the global prevalence of ILD increased from 23.1 per 100,000 in 2005 to 32.6 per 100,000 in 2020, indicating a growing public health concern. Therapeutic strategies for ILD include antifibrotic agents like pirfenidone and nintedanib, corticosteroids, and immunosuppressants. The growing focus on precision medicine, regenerative therapies, and advanced imaging techniques is expected to drive market expansion. According to the interstitial lung disease pipeline analysis by Expert Market Research, various companies are actively developing novel treatments, indicating a robust pipeline and promising growth in the coming years.
Major companies involved in the interstitial lung disease pipeline analysis include Guangzhou JOYO Pharma Co., Ltd., Boehringer Ingelheim, and others.
Leading drugs currently in the pipeline include SC1011, HEC585, PMG1015, and others.
The interstitial lung disease drug pipeline is expanding due to increasing clinical trials for antifibrotic therapies, novel biologics targeting inflammatory pathways, and rising investments in precision medicine approaches for ILD management.
The Interstitial Lung Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into interstitial lung disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for interstitial lung disease. The interstitial lung disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The interstitial lung disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with interstitial lung disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to interstitial lung disease.
Read more about this report - Request a Free Sample
Interstitial lung disease (ILD) is a group of disorders characterized by inflammation and scarring of the lung interstitium, the tissue surrounding air sacs. It occurs due to autoimmune diseases, environmental exposures, medications, or idiopathic causes, leading to impaired oxygen exchange and progressive respiratory decline.
Interstitial lung disease treatment primarily involves antifibrotic and immunomodulatory therapies. Nintedanib and pirfenidone slow disease progression, while drugs like mycophenolate mofetil, tocilizumab, and rituximab manage connective tissue disease-associated ILD. Therapy choice depends on ILD type, severity, and patient-specific factors.
In the interstitial lung disease drug pipeline, nintedanib (Ofev) and pirfenidone (Esbriet) are being actively investigated for multiple subtypes. Clinical studies continue to evaluate their effectiveness in slowing lung function decline and enhancing patient outcomes, thereby, expanding therapeutic options for progressive fibrotic ILDs. Currently, the FDA has approved nintedanib (Ofev) and pirfenidone (Esbriet) for the treatment of idiopathic pulmonary fibrosis and certain other progressive fibrotic ILDs.
According to Francesco Puppo et al., 2024, global interstitial lung disease (ILD) prevalence increased from 23.1 per 100,000 in 2005 to 32.6 per 100,000 in 2020. Malik A. Althobiani et al., 2024, reported an 86% rise in ILD-related mortality, with global prevalence ranging from 6.3 to 97.9 per 100,000 and incidence from 1 to 50 per 100,000 per year. Sarcoidosis and idiopathic pulmonary fibrosis are most common in Europe and North America, hypersensitivity pneumonitis in India and Pakistan, and connective tissue disease-associated ILD in Canada and Belgium. In Saudi Arabia, CTD-ILD accounts for 34.8% of cases, followed by IPF (23.3%), sarcoidosis (20%), and hypersensitivity pneumonitis (6.3%).
This section of the report covers the analysis of interstitial lung disease drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The interstitial lung disease pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II (with 54%) covers a major share of the total interstitial lung disease clinical trials. It is followed by phase I at 19%, and phase III at 18.72%. This robust distribution highlights strong development momentum, with advanced clinical trials driving innovation and offering potential improvements in patient outcomes, ultimately strengthening the ILD treatment landscape.
The drug molecule categories covered under the interstitial lung disease pipeline analysis include small molecules, gene therapies, peptides, proteins, and cell therapies. The interstitial lung disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for interstitial lung disease. Phosphodiesterase 4 inhibitors are gaining attention in the interstitial lung disease drug pipeline for their antifibrotic and immunomodulatory effects. For example, Nerandomilast (BI 1015550) is an orally administered selective phosphodiesterase 4B inhibitor under investigation for progressive pulmonary fibrosis. Clinical studies have shown that Nerandomilast slows lung function decline and is generally well tolerated, with diarrhea being the most common adverse event.
The EMR report for the interstitial lung disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed interstitial lung disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in interstitial lung disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for interstitial lung disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of interstitial lung disease drug candidates.
SC1011 (Sufenidone) is being sponsored by Guangzhou JOYO Pharma Co., Ltd and is currently undergoing a Phase II/III trial in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This randomized, double-blind study is examining the efficacy and safety of SC1011 compared to placebo. The study is evaluating lung function, including forced vital capacity (FVC) decline, and overall health outcomes. SC1011 is a novel pyridone derivative designed to target fibrosis, with the trial aiming to identify the optimal dose for a 52-week treatment followed by safety monitoring.
HEC585 is a pyrimidone analog derived from pirfenidone, developed by Sunshine Lake Pharma Co., Ltd., showing enhanced metabolic stability, longer half-life, and higher antifibrotic activity. This Phase IIb study is evaluating HEC585 in patients with progressive fibrosing interstitial lung disease (PF-ILD). The study is examining the efficacy and safety of two doses of HEC585 compared with placebo over a 24-week main treatment stage, followed by up to 96 weeks in an extended study. HEC585 is targeting the reduction of fibrotic biomarkers and slowing Forced Vital Capacity (FVC) decline. Preclinical data demonstrate its superior activity over pirfenidone and nintedanib in human lung fibroblasts, lung organoids, and bleomycin-induced rat lung fibrosis models, highlighting its potential as a novel therapy for PF-ILD.
Pulmongene Ltd is developing PMG1015, a first-in-class anti-AREG antibody, intended for the treatment of idiopathic pulmonary fibrosis (IPF). This Phase 1b multiple ascending dose (MAD) study is examining the safety, tolerability, pharmacokinetics, and immunogenicity of PMG1015 in IPF subjects. The study is enrolling 28 participants and is actively evaluating how the drug interacts with the immune system and targets disease mechanisms, with results expected by mid-2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Interstitial Lung Disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for interstitial lung disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into interstitial lung disease collaborations, regulatory environments, and potential growth opportunities.
Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share